Literature DB >> 12021777

In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses.

E Scott Halstead1, Yvonne M Mueller, John D Altman, Peter D Katsikis.   

Abstract

Given the key role CD8+ T cells play in controlling viral infection, strategies to enhance these responses may have important clinical applications. We found that in vivo CD137 stimulation with an agonistic monoclonal antibody enhanced the primary CD8+ T cell response to influenza type A viral infection in mice. Stimulation of CD137 increased the absolute number of CD8+ T cells to influenza epitopes in the lungs of infected animals, preferentially expanded CD8+ T cells that recognized nondominant epitopes and greatly enhanced direct ex vivo cytotoxicity. CD137 stimulation also restored the CD8+ T cell response to the immunodominant influenza epitope in CD28-/- mice. Thus, in vivo CD137 stimulation enhances and broadens the CD8+ T cell response to influenza virus and can restore the CD8+ T cell response when CD28 costimulation is absent. This suggests that CD137 stimulation may be useful as a strategy to enhance the CD8+ T cell response to viruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021777     DOI: 10.1038/ni798

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  52 in total

1.  Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.

Authors:  Lara Myers; Chikara Takahashi; Robert S Mittler; Robert J Rossi; Anthony T Vella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-14       Impact factor: 11.205

2.  CD137: costimulator turns suppressor?

Authors:  Aymen Al-Shamkhani
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

3.  CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype.

Authors:  Yuwen Zhu; Gefeng Zhu; Liqun Luo; Andrew S Flies; Lieping Chen
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

4.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells.

Authors:  Douglas V Dolfi; Alina C Boesteanu; Constantinos Petrovas; Dong Xia; Eric A Butz; Peter D Katsikis
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

6.  T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.

Authors:  Tania H Watts; Edward M Bertram; Jacob Bukczynski; Tao Wen
Journal:  Can J Infect Dis       Date:  2003-07

7.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

8.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

Review 9.  Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities.

Authors:  Matthias Wölfl; Jürgen Kuball; Matthias Eyrich; Paul G Schlegel; Philip D Greenberg
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

10.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.